• Event Type: Earnings conference call to discuss Q4 and FY25-26 financial performance and outlook.
  • Date and Time: Held on 28th May, 2026 (specific time not mentioned in the transcript).
  • Purpose: Discussion of financial performance for the quarter and year ended 31st March, 2026, and market outlook for FY27.
  • Timing Relative to Earnings: The call was held after the earnings announcement, as referenced by the submission of the audio recording on 28th May 2026.
  • Management Participants:
  • Mr. Chetan Shah, Managing Director
  • Mr. Sushil Marfatia, Executive Director
  • Dr. Suresh Ramachandran, Deputy Managing Director
  • Mr. Kunal Mittal, Senior Vice President, Planning and Coordination Office
  • Mr. Anil Nawal, Chief Financial Officer
  • Ms. Deepika Trivedi, Company Secretary and Compliance Officer
  • Colleagues from SGA, Investor Relations advisers
  • Availability of Materials: A written transcript of the earnings call was submitted to the exchanges and is available on the company's website at https://sumichem.co.in/investors-relations.php#Announcements.
  • UPSI Statement: The moderator noted that the conference call may contain forward-looking statements based on beliefs and expectations as of the call date, which are not guarantees of future performance.

Financial Highlights Discussed

FY26 Performance:

  • Revenue from operations: INR3,238 crores, up 3% YoY
  • PAT: INR543 crores, up 7% YoY
  • PBT before exceptional items: up 9% YoY
  • Gross profit margin: 42% (107 bps improvement)
  • EBITDA margin: 20.7% (64 bps improvement)
  • Net profit margin: 16.8% (68 bps improvement)
  • Cash and cash equivalents: INR2,113 crores
  • Return on capital employed: 31% (from 29%)
  • Net worth: INR3,394 crores, up 17% YoY
  • Working capital: 103 days (vs 89 days)
  • Exceptional charge: INR16.1 crores due to newly notified labor codes

Q4 FY26 Performance:

  • Revenue from operations: INR684 crores, up 1% YoY
  • Gross profit: INR289 crores, up 6% YoY
  • Gross margin: 42.3% (223 bps expansion)
  • EBITDA: INR134 crores, up 12% YoY
  • EBITDA margin: 19.6% (202 bps expansion)
  • PAT: INR111 crores, up 12% YoY
  • PAT margin: 16.3% (159 bps expansion)

Business Mix:

  • Domestic revenue grew 4% YoY in both Q4 and full year
  • Branded formulation share in domestic sales improved to 81% from 79%
  • Export revenues declined 7% in Q4 and 1% for full year
  • Insecticides: 41% of total revenue
  • Herbicides: grew 19% YoY in FY26
  • Metal phosphates: grew 11% YoY
  • Biologicals: 8-10% of revenues
  • Products launched in past 3 years contribute ~8% of domestic revenue

Product Performance:

  • Herbicides: Strong growth (87% YoY in Q4, 19% FY26) driven by flumioxazin, Lentigo, Mera 71
  • 7 new products launched during FY26 including Lentigo and Excalia Max
  • New biostimulant TopGrain received registration, to be launched upcoming months
  • Animal nutrition distribution restarted immediately with 4-5% profitability

FY27 Outlook:

  • Cautiously optimistic based on current conditions
  • Key risks: Monsoon (IMD forecast 92% of LPA, below normal), fertilizer supply, geopolitical tensions
  • Cost pressures from raw materials, packaging, solvents, transportation
  • Systematic price increases being implemented to pass on costs
  • Production running at full capacity with no supply chain constraints

Strategic Initiatives:

  • Leadership transition effective 1st September 2026:
  • Dr. Suresh Ramachandran to become Managing Director
  • Mr. Chetan Shah to become Non-Executive Chairman
  • Mr. Sushil Marfatia to retire from Board
  • New independent director: Mr. Anand Mohan Tiwari
  • Capex program: INR150 crores at Dahej site progressing well, additional projects in feasibility stage
  • India elevated to same tier as Japan, Brazil, North America, Europe for early-stage testing of new molecules
  • New royalty arrangement for 2-3 products (cap of INR2 crores, expected to be lower)
  • Custom synthesis revenue: INR100-150 crores range

Additional Notes

  • The document includes the full transcript of the earnings call with detailed management commentary and Q&A session with analysts.
  • The company confirmed that no unpublished price sensitive information was shared during the call.
  • The transcript was edited for factual errors, with audio recordings taking precedence in case of discrepancy.
  • Foreign currency exposure is largely self-hedging with exports and imports approximately equal (USD 70-80 million each annually).